Annals of Nuclear Medicine

, Volume 18, Issue 7, pp 627–630 | Cite as

Pathologic hepatic Tc-99m-MDP uptake in polyostotic fibrous dysplasia

  • Ersrsoy Kekilli
  • Cengiz Yagmur
  • Akin Kuzucu
  • Omer Soysal
  • Ayse Sertkaya Cikim
  • Kadir Ertem
Case Report


Fibrous dysplasia of bone is a congenital, sporadic developmental disorder characterized by immature fibrous connective tissue and bone deformities. Hepatic Tc-99m-MDP uptake is a rare, serendipitous finding during bone scanning studies. The present patient was a 25-year-old male who had severe polyostotic fibrous dysplasia. On Tc-99m-MDP (methylene diphosphonate) bone scintigraphy, increased activity accumulations were seen on multiple ribs, vertebrae and base of the cranium. In addition, diffuse increased pathologic uptake of Tc-99m-MDP in the liver was shown. Intravenous pamidronate was administered monthly for two months. In the third week of the last administration Tc-99m-MDP bone scintigraphy was performed again, but despite sustained bone involvement, pathologic hepatic uptake was not seen on the scan. We thought that pathologic hepatic Tc-99m-MDP accumulation, may be related to the formation and aggregation of calcium oxalate and phosphate crystals which improved with pamidromat treatment.

Key words

fibrous dysplasia hepatic extra-osseous 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kitoh H, Yamada Y, Nogami H. Different genotype of periosteal and endosteal cells of a patient with polyostotic fibrous dysplasia.J Med Genet 1999; 36: 724–725.PubMedGoogle Scholar
  2. 2.
    Favus MJ, ed.Primer on the metabolic bone diseases and disorders of mineral metabolism, 4th ed. Philadelphia;Lippincott Williams & Wilkins, 1999.Google Scholar
  3. 3.
    Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.J Clin Endocrinol Metab 2003; 88: 4569–4575.PubMedCrossRefGoogle Scholar
  4. 4.
    Resnick D.Diagnosis of bone and joint disorders, 3rd ed. Philadelphia; WB Saunders, 1995.Google Scholar
  5. 5.
    Charpurlat RD, Meunier PJ. Fibrous dysplasia of bone.Bailiere’s Clin Rheumatol 2000; 14: 385.CrossRefGoogle Scholar
  6. 6.
    Eagel BA, Stier SA, Wakem C. Non-osseous bone scan abnormalities in multiple myeloma associated with hyper-calcemia.Clin Nucl Med 1988; 13: 869–873.PubMedCrossRefGoogle Scholar
  7. 7.
    Cronhjort M, Saaf M, Sjoberg HE, Schnell PO, Jacobsson H. Influence of the phosphate balance on the activity distribution of99mTc-hydroxymethylene diphosphonate. Experimental studies in the mouse.Acta Radiol 1998; 39: 427–433.PubMedGoogle Scholar
  8. 8.
    Evans JC, Murphy M, Eyes B. Extensive soft tissue uptake of99Tcm methylene diphosphonate in a patient with multiple myeloma.Br J Radiol 2000; 73: 1018–1020.PubMedGoogle Scholar
  9. 9.
    Posch TJ, Olson SP. Marked soft tissue uptake of bone tracer in a patient with amyloidosis and multiple myeloma.Clin Nucl Med 1992; 17: 909.PubMedCrossRefGoogle Scholar
  10. 10.
    Hwang GJ, Lee JD, Park CY, Lim SK. Reversible extraskeletal uptake of bone scanning in primary hyperparathyroidism.J Nucl Med 1993; 37: 469–471.Google Scholar
  11. 11.
    Peller PJ, Ho VB, Kransdorf MJ. Extraosseous Tc-99m MDP uptake: a pathophysiologic approach.Radiographies 1993; 13: 715–734.Google Scholar
  12. 12.
    De Francisco AM, Cassidy MJ, Owen JP, Ellis HA, Farndon JR, Ward MK, et al. Ectopic calcification. The role of parathyroid hormone.Proc EurDial Transplant Assoc Eur Ren Assoc 1985; 21: 888–894.Google Scholar
  13. 13.
    Bykov S, Garty I, Bisharat N. Transient Tc-99m MDP hepatic uptake induced by acute hypoxic hepatitis.Clin Nucl Med 2001; 26: 550–551.PubMedCrossRefGoogle Scholar
  14. 14.
    Cardaci GT, Van der Schaaf A. Hepatic uptake of Tc-99mMDP in ischemie hepatitis.Clin Nucl Med 1993; 18: 906–907.PubMedCrossRefGoogle Scholar
  15. 15.
    Munoz SJ, Nagelberg SB, Green PJ, Angstadt JD, Yang SL, Jarrell BE, et al. Ectopic soft tissue calcium deposition following liver transplantation.Hepatology 1988; 8: 476–483.PubMedCrossRefGoogle Scholar
  16. 16.
    Palmer AM, Watt I, Dieppe PA. Soft-tissue localization of99mTc-hydroxymethylene diphosphonate due to interaction with calcium.Clin Radiol 1992; 45: 326–330.PubMedCrossRefGoogle Scholar
  17. 17.
    Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mstl kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.J Biol Chem 1999; 274: 34967–34973.PubMedCrossRefGoogle Scholar
  18. 18.
    Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorptionin vitro and in experimental hypercalcemia models.Bone 1995; 16: 235–245.PubMedCrossRefGoogle Scholar
  19. 19.
    Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis.Osteoporos Int 1999; 9: 489–493PubMedGoogle Scholar
  20. 20.
    Fleisch H. Bisphosphonates: mechanisms of action.Endocr Rev 1998; 19: 80–100.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2004

Authors and Affiliations

  • Ersrsoy Kekilli
    • 1
  • Cengiz Yagmur
    • 1
  • Akin Kuzucu
    • 2
  • Omer Soysal
    • 2
  • Ayse Sertkaya Cikim
    • 4
  • Kadir Ertem
    • 3
  1. 1.Departments of Nuclear MedicineInonu University, Turgut Ozal Medical Center7. km. MalatyaTurkey
  2. 2.Departments of Thoracic SurgeryUK
  3. 3.Departments of EndocrinologyUK
  4. 4.Orthopedic and TraumatologyInonu University, Turgut Ozal Medical CenterMalatyaTurkey

Personalised recommendations